Standard Treatment Approach for Suspected Malignant Pancreatic Mass

Diagnostic Evaluation

The European Society for Medical Oncology recommends initial evaluation with abdominal ultrasound to identify the pancreatic mass 3
The American College of Radiology recommends contrast-enhanced multi-detector CT (MD-CT) or MRI with MRCP for further evaluation, using a defined pancreas protocol with triphasic cross-sectional imaging and thin slices (3mm) 1, 4
Endoscopic ultrasound (EUS) complements staging by providing information on vessel invasion and lymph node involvement, as recommended by the European Society for Medical Oncology 1, 2
MD-CT of the chest is recommended to evaluate potential lung metastases, according to the European Society for Medical Oncology 1
The National Comprehensive Cancer Network recommends PET scan has no role in the diagnosis of pancreatic cancer but may be considered after formal pancreatic CT protocol in "high-risk" patients 1, 4

The European Society for Medical Oncology states that surgical resection is the only curative treatment for suspected malignant pancreatic masses, primarily suitable for patients with early-stage disease (stage I and some stage II) 1, 2
For pancreatic head tumors, the European Society for Medical Oncology recommends partial pancreaticoduodenectomy (Whipple procedure) 1
For pancreatic body/tail tumors, the European Society for Medical Oncology recommends distal resection of the pancreas 1
Standard lymphadenectomy should be performed (not extended), as recommended by the European Society for Medical Oncology 1
Postoperatively, the European Society for Medical Oncology recommends 6 months of gemcitabine or 5-FU chemotherapy 1, 2

The European Society for Medical Oncology suggests that neoadjuvant chemotherapy or chemoradiotherapy may benefit patients with larger tumors and/or vessel encasement 1, 2
This approach may achieve downsizing of the tumor and convert it to become resectable, according to the European Society for Medical Oncology 1

The European Society for Medical Oncology recommends gemcitabine treatment in conventional dosing (1000 mg/m² over 30 min) for patients with locally advanced (nonresectable Stage II or Stage III) adenocarcinoma of the pancreas 1
Biliary obstruction should be relieved via endoscopic stent placement, as recommended by the British Society of Gastroenterology 3

The National Comprehensive Cancer Network recommends that decisions about diagnostic management and resectability should involve multidisciplinary consultation 4
Resections should be performed at institutions that perform a large number (15-20) of pancreatic resections annually, as recommended by the National Comprehensive Cancer Network 4
The European Society for Medical Oncology states that elderly patients can benefit from radical surgery, but comorbidity may be a reason to abstain from resection, especially in patients older than 75-80 years 1
Diagnostic staging laparoscopy may be used to rule out subradiologic metastases, especially for body and tail lesions, according to the National Comprehensive Cancer Network 4
The European Society for Medical Oncology recommends that chemoradiation in the adjuvant setting should only be performed within randomized controlled clinical trials 1

The British Society of Gastroenterology recommends that for obstructive jaundice, endoscopic stent placement is preferable to trans-hepatic stenting 3
Most patients requiring relief of obstructive jaundice will be adequately treated by placement of a plastic stent; surgical bypass may be preferred in patients likely to survive more than six months, as recommended by the British Society of Gastroenterology 3
Duodenal obstruction should be treated surgically, according to the British Society of Gastroenterology 3
If a stent is placed prior to surgery, it should be of the plastic type and placed endoscopically, as recommended by the British Society of Gastroenterology 3